3rd Cancer Cachexia Conference: Translating Basic Mechanisms to Therapy

第三届癌症恶病质会议：将基本机制转化为治疗

• 批准号: 9195512
• 负责人: Denis C Guttridge
• 金额: $ 1万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9195512
• 关键词: Academia; Acquired Immunodeficiency Syndrome; Address; Adipose tissue; Advanced Malignant Neoplasm; Animal Model; Anticachexia Agent; Automobile Driving; Awareness; Basic Science; Biological Markers; Body Weight decreased; Boston; Cachexia; Canada; Cancer Patient; Cells; Cellular Metabolic Process; Cessation of life; Chronic Disease; Chronic Obstructive Airway Disease; Clinic; Clinical; Clinical Trials; Clinical Trials Design; Complement; Data Set; Development; Diabetes Mellitus; Diagnosis; Dietary Intervention; Disease; District of Columbia; Event; Fatigue; Fatty acid glycerol esters; Feedback; Funding; Goals; Growth; Health; Heart failure; Industry; Inflammatory Bowel Diseases; International; Journals; Kidney Failure; Knowledge; Laboratories; Malignant Neoplasms; Massachusetts; Medicine; Methods; Molecular; Morbidity - disease rate; Muscle; Muscular Atrophy; National Cancer Institute; Nature; Outcome; Outcome Measure; Palliative Care; Pathway interactions; Patients; Phase III Clinical Trials; Physicians; Positioning Attribute; Predisposition; Proteome; PubMed; Publications; Publishing; Quality of life; Questionnaires; Scientist; Shapes; Side; Skeletal Muscle; Surgical Oncologist; Syndrome; Time; Tissues; Translating; Tumor Burden; Weight; Weight Gain; advanced disease; base; bone; cancer cachexia; cancer therapy; combat; curative treatments; design; end of life; functional outcomes; improved; improved outcome; lectures; meetings; mortality; muscle form; novel strategies; novel therapeutics; oncology; outcome forecast; place fields; pre-clinical; programs; response; standard of care; success; symposium; unpublished works; wasting; whole genome

ABSTRACT Cachexia is a debilitating syndrome of cancer, characterized by involuntary weight loss resulting mainly from the depletion of skeletal muscle and adipose tissue. Estimates suggest that up to 80% of all cancers present with this syndrome, and 20% of cancer deaths are due to cachexia rather than directly from the tumor burden. By definition, weight loss > 5% is considered cachectic, but it is not uncommon for patients to lose 20-25% of their pre-illness weight. Continual weight loss associates with a poor prognosis and cachexia patients are typically weak and fatigue, which also lowers their quality of life and complicates standard of care. Nutritional interventions stimulate some weight gain in patients, but this weight is mostly transient in the form of adipose, while the loss of lean muscle cannot be reversed. Therefore, there remains an urgent need to develop more effective cachexia therapies that can translate to a better quality of life and improved outcome and survival. As there is no effective cure for this syndrome, cancer cachexia remains largely viewed as an end-of-life condition in patients with advanced malignancies that can be managed primarily through palliative care approaches. These and other observations underscore the importance of identifying new methods for the design of effective strategies to combat this deadly syndrome. Many of the new therapies that will be developed for cancer cachexia will likely come on identifying targets that contribute to the underlying mechanisms of muscle and fat loss. Over the years, there has certainly been significant growth in the identification of these targets, and importantly, a number of these discoveries have come from new laboratories entering the field and published in impact journals such as Nature, Cell, Nature Medicine, and Cell Metabolism. In addition, support from the National Institutes of Cancer and the Provocative Questions mechanism further contributed to the expansion of the field from both the basic and clinical side. Lacking however was a forum where scientist could come together to exchange ideas and discuss the latest unpublished findings. This forum was created in 2012 with the organization of the 1st International Cancer Cachexia conference held in Boston, Massachusetts. Based on the feedback received and the successes of this first meeting, a 2nd conference was organized in 2014 in Montreal, Canada. With strong registration numbers and enthusiastic responses from those who attended, the decision was made to organize the 3rd International Cancer Cachexia Conference that this time will be held in Washington DC. The goals of this third conference is to 1) enhance the understanding of the underlying mechanisms of cancer cachexia, emphasizing cross talk between tissues and analysis of large data sets; and 2) to educate on the need for better effective pre-clinical and clinical trial design and outcome measures. Achieving these goals will place the field in a better position to accelerate the development of anti-cachexia therapies.

抽象的 恶氧化疾病是癌症的衰弱综合征，其特征是非自愿体重减轻，主要由 骨骼肌和脂肪组织的耗竭。估计表明，在所有癌症中，多达80％ 由于这种综合征，癌症死亡中有20％是由于恶病质，而不是直接来自肿瘤负担。 根据定义，体重减轻> 5％被认为是缓存的，但患者损失20-25％并不少见 他们的重量。连续减肥的伴侣与预后不良，缓存患者是 通常疲劳和疲劳，这也降低了其生活质量并使护理标准复杂化。营养 干预措施刺激了患者的体重增加，但这种体重主要是以脂肪形式的短暂性， 虽然瘦肌肉的损失无法逆转。因此，迫切需要发展更多 有效的恶病质疗法可以转化为更好的生活质量，改善结果和生存。作为 该综合征没有有效的治疗 在患有晚期恶性肿瘤的患者中，可以主要通过姑息治疗方法进行管理。 这些和其他观察结果强调了确定新方法设计有效的新方法的重要性 打击这种致命综合症的策略。许多将为癌症开发的新疗法 恶病质可能会识别有助于肌肉和脂肪的潜在机制的靶标 损失。多年来，这些目标的识别肯定已经显着增长，并且 重要的是，其中许多发现来自进入该领域并发表的新实验室 影响自然，细胞，自然医学和细胞代谢等期刊。此外，来自 国立癌症研究所和挑衅性问题机制进一步促进了扩张 基本和临床方面的领域。但是缺少一个论坛，科学家可以来 共同交流想法并讨论最新未发表的发现。这个论坛是在2012年创建的 在马萨诸塞州波士顿举行的第一届国际癌症恶病质会议的组织。基于 收到的反馈和第一次会议的成功，2014年举行了第二次会议 加拿大蒙特利尔。有强大的注册人数和参加者的热情回应 决定组织第三次国际癌症恶病质会议，这次将举行 华盛顿特区第三次会议的目标是1）增强对基础的理解 癌症恶病质的机制，强调组织之间的交叉谈话和大型数据集的分析；和 2）教育需要更好地有效的临床前和临床试验设计和结果指标。 实现这些目标将使该领域更好地加速抗激活的发展 疗法。